Last reviewed · How we verify
Bivalent OPV 2 week interval
Bivalent OPV provides immunization against poliovirus types 1 and 3 by stimulating the immune system to produce antibodies against these two serotypes.
Bivalent OPV provides immunization against poliovirus types 1 and 3 by stimulating the immune system to produce antibodies against these two serotypes. Used for Poliomyelitis prevention (poliovirus types 1 and 3).
At a glance
| Generic name | Bivalent OPV 2 week interval |
|---|---|
| Sponsor | International Centre for Diarrhoeal Disease Research, Bangladesh |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Bivalent oral polio vaccine (bOPV) contains live attenuated poliovirus strains of types 1 and 3. When administered orally, it replicates in the intestinal tract and induces both mucosal (IgA) and systemic (IgG) immune responses. The 2-week interval dosing schedule is designed to optimize immune response and achieve high population immunity levels for polio eradication.
Approved indications
- Poliomyelitis prevention (poliovirus types 1 and 3)
Common side effects
- Vaccine-strain poliovirus shedding in stool
- Mild gastrointestinal symptoms
- Fever
Key clinical trials
- Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine (PHASE3)
- Poliovirus Vaccine Trial in Bangladesh (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: